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S238 Poster Session IWe have for the first time, using a rapid isolation protocol of EBV-
specific T cells, treated and cured a patient suffering from PTLD
with multiple associated tissue lesions, using her haplo-identical
mother as a donor. This treatment approach paves way for a new pos-
sibility to within days treat patients with life-threatening EBV-asso-
ciated malignancies.215
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Background: For aggressive lymphomas a T-cell phenotype confers
a poor prognosis. Current therapeutic strategies for T-cell non-
Hodgkin lymphoma (NHL) are poorly defined. Allogeneic stem
cell transplantation (Allo-HCT) is a potentially curative option but
associated with high non-relapse mortality (NRM). Reduced inten-
sity conditioning (RIC) is designed to minimize NRM while using
the benefits of the graft-versus-lymphoma effect. Here we report ret-
rospective analysis of patients with T-cell NHL who underwent
Allo-HCT with RIC using fludarabine and melphalan.
Patients andMethods:A consecutive case-series of 27 patients with
mature T-cell NHLwere included. All patients underwent RICwith
fludarabine and melphalan. Histologies included: PTCL NOS
(n5 5); AILD (n5 3); ALCL (n5 2; both alk+); rare histologies
(n5 6) (NK/T cell, enteropathy type, hepatosplenic); and cutaneous
T-cell lymphomas (n5 11). Most patients (n5 18, 67%) had ad-
vanced disease at the time of transplant: relapse/induction fail-
ure5 17, progression5 1. The rest of the patients were in
CR15 1, CR25 5, PR5 3. The median age was 50 years (range:
19-68), 74% were male (n5 20). The time from diagnosis to trans-
plant for majority of the patients (n5 20, 74%) was more than one
year. The median number of prior regimens was 4 (range: 1-9);
one patient had a prior autologous transplant. All patients received
stem cells, 56% from HLA-matched sibling and 44% from matched
unrelated donor. 18 patients (67%) received GVHD prophylaxis
with sirolimus/tacrolimus, while 9 patients (33%) received cyclo-
sporine/cellcept based prophylaxis.
Results: The median follow-up for the 16 (59%) surviving pa-
tients was 24.2 months (range: 5.6-95.3). Day 100 mortality
was 22% (n5 6). There were a total of 11 deaths; 5 from dis-
ease progression/relapse and 6 from non-relapse causes. 13 pa-
tients (48%) experienced acute GVHD: grade I5 4, grade
II5 5, grade IV5 4. Among the 17 patients who are evaluable
for chronic GVHD, 11 (63%) patients developed an extensive
GVHD. The 2-year probability of overall (OS) and disease-
free (DFS) survival were 55% (95%CI: 43-65%) and 43%
(95%CI: 34-52%) respectively. The relapse/progression and
NRM rates at 2 years were 37% (95%CI: 26-52%) and 28%
(95%CI: 16-46%) respectively.
Conclusion: The overall results show that good long term survival
rates and disease control can be achievedwith acceptable non-relapse
mortality in patients with mature T-cell lymphomas using reduced
intensity conditioning.216
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Patients (pts) with T-NHL have a poor prognosis with standard
chemotherapy. HSCT have been used in their management but
the most appropriate time for HSCT is not clear. We previously re-
ported the poor outcome of pts with ALK negative (anaplastic lym-
phoma kinase) anaplastic large cell lymphoma (ALCL) having
HSCT after first recurrence (Zamkoff et al, BMT 33:635-8,2004).To further investigate outcomes of pts transplanted for T-NHL,
we retrospectively analyzed 33 pts undergoing autologous HSCT
from August 2000 to July 2009. 23 were male, 10 female; median
age was 53.2 (29 -73) years at time of HSCT. Subtypes of T-NHL
included Alk negative ALCL (9) and Alk positive ALCL (1); periph-
eral T-Cell (PTCL), not otherwise specified (11); Angioimmuno-
blastic (AILT) (9); Nasal NK/T (2) and cutaneous T-cell (CTCL)
(1). 6 pts were in their first complete remission (CR1), 1 in CR1 un-
confirmed (CRU1), 10 in first partial remission (PR1), 9 in first re-
lapse (Rel1) with 8 sensitive and 1 refractory, 3 in CR2, and 4 in
second or later sensitive relapse (Rel2+). Preparative regimens for
HSCT included Cy/TBI (13) or Cy/etoposide/TBI (9), Bu/Cy (6),
CBV (4), and BEAM (1).
Among the 12 pts in CR1/CRU1 or PR1\200 days from diagno-
sis (Group 1), there were 2 with Alk negative ALCL, 5 PTCL, 4
AILT, and 1 Nasal NK/T. Among the 21 pts (Group 2), there
were 7 with Alk negative ALCL, 1 Alk positve ALCL, 6 PTCL, 5
AILT, 1 Nasal NK/T, and 1 CTCL.
With a median follow-up of 17.6 (0.4-84.0) months post
HSCT, the overall survival (OS) is estimated to be 52% and pro-
gression free survival (PFS) is 45%. 16 pts have expired. Causes of
death include relapse (12), transplant related mortality (1), second
malignancy (1), and unknown (2) since no MD follow-up records
available.
Among the 17 surviving pts, 10 were among the 12 pts in
Group 1. For this group, the OS is 83% with a PFS of 75% at
a median follow-up of 18.6 (0.7-60.5) months. 7 additional pts
survive among the Group 2 pts; their OS is 33% and PFS is
29% at a median follow-up of 15.2 (13-84) months. In Group
2, surviving pts include 1 of 3 transplanted in CR2; 6 of 13 trans-
planted in Rel1 or Rel2+ and 0 of 5 in PR1 transplanted .200
days from diagnosis.
In summary, this data would suggest an improved outcome for
HSCT in pts withT-NHLwhen applied earlier in the course of their
disease. Such a strategy should be evaluated in a larger prospective
trial of HSCT in CR1/PR1 to evaluate the efficacy and safety across
the various subtypes T-NHL.217
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Background: Patients with symptomatic relapsed follicular lym-
phoma, together with their physicians, must choose between a va-
riety of treatment options. The purpose of this study was to elicit
relative preferences for attributes associated with different treat-
ment options amongst lymphoma patients in Alberta, and lym-
phoma-treating physicians in Canada, using a discrete choice
experiment (DCE).
Methods: 180 patients aged 18-65 years and 252 physicians re-
ceived background information and a questionnaire containing
the DCE. Treatment administration, toxicity, average remission
length, and cost were the attributes evaluated for four treatment
options: standard chemotherapy (CT), radioimmunotherapy
(RIT), high-dose chemotherapy and autologous (AUTO) or allo-
geneic (ALLO) stem cell transplantation. In a series of multiple
choice questions, respondents were asked to choose between
two unlabeled treatment options, described according to the attri-
butes where the attribute levels were different for each option.
The DCE was analyzed using a random effects logit model. Mar-
ginal rates of substitution calculated from regression coefficients
provided information about preference for the treatment attri-
butes.
Results: 81 patients (45%) and 48 physicians (19%) completed the
questionnaire. Responding patients had a mean age of 54.7 years
and were on average 4.4 years from initial diagnosis. 93% of patients
